KAINOS MEDICINE terminates 990M KRW i-Ject supply contract due to non-payment, raising loss concerns
KAINOS MEDICINE disclosed the termination of a supply contract for painless auto-injector (i-Ject) with LT9 Enterprises Limited. The contract amount was approximately 990.5 million KRW, representing 167.78% of its 2024 consolidated sales (590 million KRW).
The termination reason is that the company had already fulfilled its obligations, but the counterparty failed to pay by the contract end date (2026-05-29). This indicates credit risk and potential impairment of trade receivables.
The company plans to seek recovery of goods or payments through legal review and consultation, but the outstanding receivable poses near-term negative cash flow impact.
Coupled with the recent treasury stock disposal (2026-04-30), this contract termination could act as a near-term negative factor for the stock price. Investors should monitor recovery progress and potential additional losses.
[AI Comprehensive Analysis]This contract termination is not just a simple end of agreement but implies actual potential losses due to non-payment for already fulfilled deliveries. Given the large contract size relative to sales, it may burden corporate value. Short-term stock price is negatively affected, but recovery success will be a key variable for future direction.
KOSDAQ Filing Information
Filing: [Correction of Description] Termination of Single Sale and Supply Contract